title: Treatment of hepatitis C infection in patients with renal disease.
abstract: Hepatitis C virus infects 20-40% of the end-stage renal disease population, and has been associated with essential mixed cryoglobulinemia and several forms of immune-complex glomerulonephritis. Overall, treatment with interferon alpha has been disappointing, although certain situations may benefit from dosing regimens that differ in the amount of drug and duration of treatment from the conventional interferon doses currently recommended for non-renal patients.
authors.affiliation: Division of Nephrology and Hypertension, University of Miami School of Medicine, FL, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Diego
authors.forename: D
authors.initials: D
authors.lastname: Roth
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006526:Hepatitis C / Q000150:complications / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D016030:Kidney Transplantation; D011994:Recombinant Proteins; D006435:Renal Dialysis
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins